Intravenous immunoglobulin therapy for autoimmune diseases

被引:51
作者
Arnson, Yoav [1 ]
Shoenfeld, Yehuda [2 ]
Amital, Howard [1 ]
机构
[1] Tel Aviv Univ, Dept Med D, Sackler Fac Med, Meir Med Ctr, IL-95847 Kefar Sava, Israel
[2] Tel Avi Univ, Sackler Fac Med, Dept Internal Med B, Ctr Autoimmune Dis,Sheba Med Ctr, Tel Hashomer, Israel
关键词
Intravenous immunoglobulins; autoimmune diseases; SYSTEMIC-LUPUS-ERYTHEMATOSUS; GUILLAIN-BARRE-SYNDROME; IDIOPATHIC THROMBOCYTOPENIC PURPURA; CROSS-REACTIVE IDIOTYPE; GAMMA-GLOBULIN; MULTIPLE-SCLEROSIS; IMMUNE GLOBULIN; PLASMA-EXCHANGE; ANTIPHOSPHOLIPID ANTIBODIES; PEMPHIGUS-VULGARIS;
D O I
10.1080/08916930902785363
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Therapeutic approaches for autoimmune diseases are primarily based on suppressive measures that down regulate an over productive immune system. The increasing availability of modern biological therapies has advanced the ability to target and to neutralize essential components of the immune response without experiencing the hazardous adverse effects caused by the traditional immunosuppressants. One of the noticeable examples of this approach is the increasing use of high-dose intravenous immunoglobulin (IVIg). IVIg mechanisms include modulating function of Fc receptors, interference with complement activation and cytokine network, provision of anti-idiotypic antibodies, regulation of cell growth, and effects on of T and B cells. In this review we gather existing information regarding IVIg mechanisms of action, clinical applications and its effects on various conditions.
引用
收藏
页码:553 / 560
页数:8
相关论文
共 75 条
[1]  
ADIB M, 1990, J IMMUNOL, V145, P3807
[2]   Successful treatment of early secondary myelofibrosis in SLE with IVIG [J].
Aharon, A ;
Levy, Y ;
BarDayan, Y ;
Afek, A ;
ZandmanGoddard, G ;
Skurnik, Y ;
Fabrizzi, F ;
Shoenfeld, Y .
LUPUS, 1997, 6 (04) :408-411
[3]  
AKASHI K, 1990, J RHEUMATOL, V17, P375
[4]   THE EFFECT OF INTRAVENOUS GAMMA-GLOBULIN ON THE INDUCTION OF EXPERIMENTAL ANTIPHOSPHOLIPID SYNDROME [J].
BAKIMER, R ;
GUILBURD, B ;
ZURGIL, N ;
SHOENFELD, Y .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1993, 69 (01) :97-102
[5]   F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins:: a novel effector function of immunoglobulins [J].
Basta, M ;
Van Goor, F ;
Luccioli, S ;
Billings, EM ;
Vortmeyer, AO ;
Baranyi, L ;
Szebeni, J ;
Alving, CR ;
Carroll, MC ;
Berkower, I ;
Stojilkovic, SS ;
Metcalfe, DD .
NATURE MEDICINE, 2003, 9 (04) :431-438
[6]  
BECKER BN, 1995, J AM SOC NEPHROL, V5, P1746
[7]   Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis [J].
Boletis, JN ;
Ioannidis, JPA ;
Boki, KA ;
Moutsopoulos, HM .
LANCET, 1999, 354 (9178) :569-570
[8]   Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome [J].
Bril, V ;
Ilse, WK ;
Pearce, R ;
Dhanani, A ;
Sutton, D ;
Kong, K .
NEUROLOGY, 1996, 46 (01) :100-103
[9]   Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease [J].
Bruhns, P ;
Samuelsson, A ;
Pollard, JW ;
Ravetch, JV .
IMMUNITY, 2003, 18 (04) :573-581
[10]  
BUSSEL JB, 1983, BLOOD, V62, P480